Handheld Emergency Asthma Drug Device

SAIT理工学院正在申请NSERC应用研究和开发资助的项目， 推进新药S-1226 TM的新型加压单剂量给药装置的开发 由SolAeroMed Inc.用于治疗严重哮喘。在未来，该药物还有望 治疗慢性阻塞性肺疾病（COPD）和囊性纤维化的恶化。SolAeroMed Inc.，一 一家小型阿尔伯塔公司，此前曾与SAIT的应用研究和创新服务部门合作， 为公司的临床试验创造一种新的输送系统。SolAeroMed已完成临床前研究 I期临床试验显示S-1226 TM在所有剂量水平均有效且安全; IIa期临床试验显示S-1226 TM在所有剂量水平均有效且安全。 目前正在进行临床试验，以证明概念的证据。 目前市场上还没有能够满足公司需求的点胶技术。的部件 新的药物必须在设备内进行特定的组合，并从设备中推出，并到达患者的肺部 在短时间内，为急性哮喘发作提供更有效和更持久的缓解。 该设备的开发将大大有助于该公司的商业化。

SAIT Polytechnic is requesting NSERC Applied Research and Development grant funding for a project to advance the development of a novel pressurized single dose delivery device for S-1226TM, a new drug developed by SolAeroMed Inc. for the treatment of severe asthma. In the future the drug is also expected to treat exacerbations of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. SolAeroMed Inc., a small Alberta company, has previously engaged with Applied Research and Innovation Services at SAIT to create a novel delivery system for the company's clinical trials. SolAeroMed has completed preclinical studies and a Phase I clinical trial showing that S-1226TM is effective as well as safe at all dosing levels; a Phase IIa clinical trial to demonstrate proof of concept is currently underway. There is no dispensing technology on the market today that meets the company's needs. The components of the new drug must be specifically combined within and propelled from the device, and reach the patient's lungs within a short period of time, to provide a more effective and longer lasting relief of acute asthma attacks. Development of the device will greatly assist the company's commercialization.